Abstract
We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity on BNT162b2 mRNA COVID-19 vaccine reactogenicity. Of 96 healthcare workers (HCWs), 76% reported any vaccine reaction (first dose: 70%, second dose: 67%), none of which was severe. Following first dose, systemic reactions were significantly more frequent among HCWs with past infection than in infection-naïve individuals, and among HCWs with pre-existing cellular immunity than in those without it. The rate of systemic reactions after second dose was 1.7 and 2.0-times higher than after first dose among infection-naïve HCWs and those without pre-existing cellular immunity, respectively. Levels of SARS-CoV-2-specific T-cells before vaccination were higher in HCWs with systemic reactions after the first dose than in those without them. BNT162b2 vaccine reactogenicity after first dose is attributable to pre-existing cellular immunity elicited by prior COVID-19 or cross-reactivity. Reactogenicity following second dose suggests an immunity-boosting effect. Overall, these data may reduce negative attitudes towards COVID-19 vaccines. Study Registration. The study was registered on clinicaltrials.gov, NCT04402827 .
Keywords: BNT162b2 mRNA vaccine; Booster effect; COVID-19; Reactogenicity; SARS-CoV-2; T-cell responses.
【저자키워드】 COVID-19, SARS-CoV-2, reactogenicity, T-cell responses, BNT162b2 mRNA vaccine, Booster effect, 【초록키워드】 Vaccine, BNT162b2 vaccine, COVID-19 vaccine, vaccination, Infection, healthcare worker, cross-reactivity, Registration, COVID-19 vaccines, cellular immunity, HCWs, T-cell, T-cell responses, BNT162b2 mRNA, HCW, systemic reaction, second dose, These data, first dose, Registered, examined, significantly more, reported, reduce, individuals, elicited, Level, 【제목키워드】 COVID-19 vaccine, Immunity, BNT162b2 mRNA,